Alyeska Investment Group
KYMR icon

Alyeska Investment Group’s Kymera Therapeutics KYMR Stock Holding History

Alyeska Investment Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.5M Sell
342,698
-29,191
-8% -$2.31M 0.08% 267
2025
Q4 		$28.9M Sell
371,889
-243,202
-40% -$16.4M 0.08% 260
2025
Q3 		$34.8M Buy
615,091
+565,091
+1,130% +$25.5M 0.11% 215
2025
Q2 		$2.18M Buy
+50,000
New +$1.72M 0.01% 479
2022
Q2 		– Sell
-183,750
Closed -$7.78M – 620
2022
Q1 		$7.78M Buy
183,750
+57,457
+45% +$2.43M 0.09% 237
2021
Q4 		$8.02M Buy
126,293
+1,293
+1% +$75.3K 0.09% 212
2021
Q3 		$7.34M Buy
+125,000
New +$7.25M 0.09% 255

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Alyeska Investment Group's KYMR Position: Q1 2026 in Review

Alyeska Investment Group reduced its Kymera Therapeutics (KYMR) stake by 7.8% in Q1 2026, selling an estimated $2.31M and leaving 342,698 shares worth $28.5M. The position accounts for 0.08% of the portfolio, ranked #267.

Alyeska Investment Group first reported a position in KYMR in Q3 2021 and has held it in 7 quarters since. The position peaked at $34.8M in Q3 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Alyeska Investment Group held 342,698 shares of Kymera Therapeutics worth $28.5M as of Q1 2026.
  • Alyeska Investment Group sold 29,191 Kymera Therapeutics shares in Q1 2026, an estimated $2.31M.
  • Kymera Therapeutics made up 0.08% of Alyeska Investment Group's portfolio in Q1 2026, its #267 holding.
  • Alyeska Investment Group first reported a position in Kymera Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • Alyeska Investment Group's Kymera Therapeutics position peaked at $34.8M in Q3 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.